Koelis

Executive Summary

Koelis is a French medical device company founded in 2008 that has established itself as a pioneer in MRI/ultrasound fusion technology for prostate cancer diagnosis and treatment. The company's core offering is a 3D prostate mapping platform that enhances the precision and safety of clinical interventions, from initial biopsy to targeted therapy. By fusing pre-operative MRI data with real-time ultrasound, Koelis provides urologists with a comprehensive tool to guide procedures, ultimately aiming to improve personalized prostate cancer care. The platform addresses a critical need in the field: reducing false negatives in biopsies and enabling more accurate focal therapy. With a strong intellectual property portfolio and a focus on the growing prostate cancer diagnostics market, Koelis has carved out a defensible niche in the medtech landscape. Despite its technological promise, Koelis faces significant challenges. The company operates in a competitive space against larger players like Philips and Eigen, and its market penetration remains limited primarily to European centers. Financial details are sparse due to its private status, but the lack of disclosed funding rounds or major commercial deals suggests a slower growth trajectory. Adoption of its platform may be hindered by the training required for clinicians and the upfront cost of the system. However, the aging population and rising prostate cancer incidence globally provide a tailwind for precision diagnostic tools. If Koelis can expand its commercial presence, particularly in the U.S., or secure partnerships with key opinion leaders, it could gain significant traction. The company's focus on improving outcomes in prostate cancer positions it well for long-term relevance, but near-term visibility remains low.

Upcoming Catalysts (preview)

• Q3 2026U.S. FDA clearance for upgraded 3D mapping software with AI-enhanced fusion60% success
• Q4 2026Strategic partnership with a major urology clinic chain for European rollout50% success
• Q1 2027Publication of pivotal clinical data demonstrating improved biopsy accuracy versus standard fusion systems70% success